Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

Regulation versus innovation in medicine 

Regulation versus innovation in medicine
Chapter:
Regulation versus innovation in medicine
Author(s):

Michael Rawlins

DOI:
10.1093/med/9780198746690.003.0025
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 02 March 2021

Two tragedies created drug regulatory authorities in the form they exist today. The marketing in 1937 of an elixir of sulphanilamide using diethyl alcohol as the solvent led to over 100 children dying from acute kidney injury. The use from 1957 of thalidomide as a treatment for morning sickness led to the development of phocomelia (and other abnormalities) in the fetuses of about 10 000 mothers who had been given it during their pregnancies. Drug regulatory authorities initially tended to be risk averse, but now recognize concern that the process of drug regulation might inhibit the development and licensing of novel products. They now pursue a more risk-based approach to regulation and seek to support safe innovation, with arrangements including scientific advice programmes, orphan drug approval processes, and expedited approval processes, although these are not without their critics.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.